Biotechnology firm REGENXBIO Inc. (NASDAQ: RGNX), currently valued at $488 million in market capitalization, has finalized a royalty bond agreement with Healthcare Royalty (HCRx), securing $150 million at closing and potentially up to $250 million in total. This financial move is aimed at extending the company’s cash runway into early 2027, as announced today.
The agreement involves monetizing anticipated royalties and milestone payments from specific assets. It allows REGENXBIO to receive immediate and future capital without diluting shareholder equity. The company has received $150 million upfront and may receive an additional $100 million based on certain conditions being met by April 30, 2027.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.